Article
Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses
2 Sept 2022
Abstract excerpt
Influenza A viruses pose a significant threat globally each year, underscoring the need for a vaccine- or antiviral-based broad-protection strategy. Here, we describe a chimeric monoclonal antibody, C12H5, that offers neutralization against seasonal and pandemic H1N1 viruses, and cross-protection against some H5N1 viruses. Notably, C12H5 mAb offers broad neutralizing activity against H1N1 and H5N1 viruses by...
Topics
Join the communities discussing this publication.